Knight Therapeutics Inc.
TSX:GUD.TODrug Manufacturers - Specialty & Generic
+$0.07 today
- Market cap
- $1.14B
- Beta
- 0.07
- P/E (TTM)
- 164.6
- EPS (TTM)
- $0.06
Volume 0.04M
Average 0.10M
Income Statement
Follow revenue through to earnings.
Revenue
$450.09M
FY 2025 · Annual
+21.2% YoYOperating Income
-$2.20M
FY 2025 · Annual
Net Income
-$5.37M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 243.48M | 293.56M | 328.2M | 371.3M | 450.09M |
| Cost of Revenue | 128.07M | 155.5M | 175.55M | 196.9M | 299.35M |
| Gross Profit | 115.41M | 138.06M | 152.65M | 174.41M | 150.74M |
| Gross Margin | 47.4% | 47.0% | 46.5% | 47.0% | 33.5% |
| Research & Development | 12.69M | 14.76M | 17.55M | 23.3M | 28.98M |
| Selling, General & Admin | 74.38M | 88.62M | 83.69M | 99.35M | 123.96M |
| Operating Expenses | 128.24M | 155.12M | 155.54M | 167.01M | 152.94M |
| Depreciation & Amortization | 47.92M | 62.62M | 50.4M | 53.11M | 56.57M |
| EBITDA | 42.59M | 25.26M | 40.9M | 64.38M | 54.37M |
| EBITDA Margin | 17.5% | 8.6% | 12.5% | 17.3% | 12.1% |
| Operating Income | (5.32M) | (2.4M) | (2.89M) | 7.4M | (2.2M) |
| Operating Margin | -2.2% | -0.8% | -0.9% | 2.0% | -0.5% |
| Interest Income | 7.38M | 10.63M | 12.58M | 10.41M | 6.21M |
| Interest Expense | 3.62M | 6.6M | 12.49M | 9.22M | 10.42M |
| Other Income / Expenses | 19.52M | (2.92M) | (19.1M) | (5.35M) | (4.5M) |
| Income Before Tax | 6.69M | (43.96M) | (21.99M) | 2.05M | (6.7M) |
| Pre-Tax Margin | 2.7% | -15.0% | -6.7% | 0.6% | -1.5% |
| Income Tax Expense | (8.99M) | (14.07M) | (5.15M) | (2.28M) | (1.33M) |
| Net Income | 15.68M | (29.89M) | (16.84M) | 4.33M | (5.37M) |
| Net Margin | 6.4% | -10.2% | -5.1% | 1.2% | -1.2% |
| EPS (Basic) | 0.13 | (0.26) | (0.16) | 0.04 | (0.05) |
| EPS (Diluted) | 0.13 | (0.26) | (0.16) | 0.04 | (0.05) |
| 124.48M | 114.89M | 107.47M | 101.04M | 99.57M | |
| 124.52M | 114.89M | 107.47M | 101.44M | 99.57M |
GUD.TO Earnings Waterfall · TTM
TSX:GUD.TO · Revenue to Net Income
Key Ratios
Analysis
$510.5M of revenue converted into $5.6M of net income for the selected period. Gross margin is 37.5% and net margin is 0.2%, showing how much revenue survives after costs and taxes. EPS is $0.05, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
No filings found.
How much revenue does GUD.TO generate?
Knight Therapeutics Inc. (GUD.TO) reported $450.09M of revenue in fiscal 2025.
Is GUD.TO profitable?
Knight Therapeutics Inc. (GUD.TO) reported -$5.37M of net income, with a net margin of -1.2%.
Continue the stock analysis
Jump to another research area for this company.